Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Non Small Cell Lung Carcinoma NSCLC 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 6Carboplatin 6Gemcitabine 3pembrolizumab 2Irinotecan 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1erythromycin propionate-N-acetylcysteinate 1entrectinib 1cobimetinib 1belinostat 1atezolizumab 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1Vemurafenib 1Surveys and Questionnaires 1Oxaliplatin 1HhAntag691 1Everolimus 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Unknown Primary × CP protocol × Clear all
NCT00873119 2015-07-28

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Valerio Therapeutics

Phase 2 Completed
89 enrolled 12 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡